Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 235,100 shares, a drop of 20.5% from the August 31st total of 295,900 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average trading volume of 289,100 shares, the short-interest ratio is presently 0.8 days.
Petros Pharmaceuticals Trading Up 4.2 %
Shares of Petros Pharmaceuticals stock traded up $0.01 during trading on Friday, hitting $0.35. The stock had a trading volume of 33,841 shares, compared to its average volume of 577,828. The stock has a 50 day simple moving average of $0.36 and a 200 day simple moving average of $0.61. The company has a market capitalization of $2.45 million, a PE ratio of -0.04 and a beta of 2.09. The company has a quick ratio of 1.26, a current ratio of 1.40 and a debt-to-equity ratio of 0.71. Petros Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $2.27.
Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter. The firm had revenue of $1.42 million for the quarter.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Read More
- Five stocks we like better than Petros Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- 10 Best Airline Stocks to Buy
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Earnings Per Share Calculator: How to Calculate EPS
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.